Recent Quotes (30 days)

You have no recent quotes
chg | %

Arch Biopartners Inc  

(Public, CNSX:ACH)   Watch this stock  
Find more results for ACH
Real-time:   9:58AM EST
CNSX real-time data - Disclaimer
Currency in CAD
Range     -
52 week 0.38 - 0.42
Open     -
Vol. 0.00
Mkt cap 21.41M
P/E     -
Div/yield     -
EPS -0.01
Shares 50.98M
Beta     -
Inst. own     -

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin - -2229.01%
Operating margin - -2409.41%
EBITD margin - -2363.44%
Return on average assets -196.15% -159.01%
Return on average equity - -1243.98%
CDP Score - -


174 Spadina Ave Suite 502A
+1-647-4287031 (Phone)
+1-905-7704454 (Fax)

Website links


Arch Biopartners Inc. is a portfolio-based biotechnology company. The Company is focused on the development of technologies. The Company's technologies include AB569, MetaMx, MetaBlok, Borg and Arch Inflammation. AB569 is a drug candidate for the treatment of Pseudomonas aeruginosa infections in the respiratory tracts of patients with Cystic Fibrosis. MetaMx is a synthetic molecule that targets brain tumor initiating cells and invasive glioma cells for the purpose of imaging, diagnosis and developing targeted therapies. MetaBlok is a drug candidate for the treatment of sepsis and cancer metastasis. Borg is a peptide-solid surface interface for binding peptides to solid surfaces to inhibit biofilm formation and reduce corrosion. Arch Inflammation is a treatment for chronic kidney and bowel diseases caused by non-infectious inflammation. The Company's subsidiaries include Arch Biotech Inc., Arch Biophysics Inc. and Arch Bio Ireland Ltd.

Officers and directors

Richard Muruve President, Chief Executive Officer, Director
Daniel Muruve Chief Science Officer
Andrew Bishop Director
Richard Rossman M.D. Director
Patrick Vink M.D. Director
Age: 51
Claude Allary Independent Director
Conor M. Gunne Independent Director